Ministry of National Guard – Health Affairs, Riyadh, Saudi Arabia
Search for other papers by Fahad Al-Juraibah in
Google Scholar
PubMed
Department of Paediatrics, Endocrine Division, Jeddah, Saudi Arabia
Search for other papers by Adnan Al Shaikh in
Google Scholar
PubMed
Search for other papers by Afaf Al-Sagheir in
Google Scholar
PubMed
Ministry of National Guard – Health Affairs, Riyadh, Saudi Arabia
Search for other papers by Amir Babiker in
Google Scholar
PubMed
Search for other papers by Asma Al Nuaimi in
Google Scholar
PubMed
Search for other papers by Ayed Al Enezi in
Google Scholar
PubMed
Search for other papers by George S Mikhail in
Google Scholar
PubMed
Search for other papers by Hassan A Mundi in
Google Scholar
PubMed
Search for other papers by Hubert K Penninckx in
Google Scholar
PubMed
Search for other papers by Huda Mustafa in
Google Scholar
PubMed
Search for other papers by Majid Al Ameri in
Google Scholar
PubMed
Ministry of National Guard – Health Affairs, Riyadh, Saudi Arabia
Search for other papers by Mohamed Al-Dubayee in
Google Scholar
PubMed
Search for other papers by Nadia S Ali in
Google Scholar
PubMed
Faculty of medicine, Sohag University, Egypt
Search for other papers by Nagla Fawzy in
Google Scholar
PubMed
Search for other papers by Sameer Al Shammari in
Google Scholar
PubMed
Search for other papers by Tarek Fiad in
Google Scholar
PubMed
Summary
X-linked hypophosphatemic rickets (XLH), the most prevalent form of inherited hypophosphatemic rickets, is caused by loss-of-function mutations in the gene encoding phosphate-regulating endopeptidase homolog, X-linked (PHEX). This case series presents 14 cases of XLH from Gulf Cooperation Council (GCC) countries. The patients’ medical history, biochemical and radiological investigative findings, as well as treatment responses and side effects from both conventional and burosumab therapy, are described. Cases were aged 2–40 years at diagnosis. There were two male cases and 12 female cases. All cases were treated with conventional therapy which resulted in a lack of improvement in or worsening of the clinical signs and symptoms of rickets or biochemical parameters. Side effects of conventional therapy included nausea, diarrhea, abdominal pain, nephrocalcinosis, and hyperparathyroidism, which affected the patients’ quality of life and adherence to treatment. In the 10 patients treated with burosumab, there was a marked improvement in the biochemical markers of rickets, with a mean increase in serum phosphate of +0.56 mmol/L and tubular maximum phosphate reabsorption (TmP) to glomerular filtration rate (GFR) ratio (TmP/GFR) of +0.39 mmol/L at 12 months compared to baseline. Furthermore, a mean decrease in serum alkaline phosphatase (ALP) of −80.80 IU/L and parathyroid hormone (PTH) of −63.61 pmol/L at 12 months compared to baseline was observed in these patients. Additionally, patients treated with burosumab reported reduced pain, muscle weakness, and fatigue as well as the ability to lead more physically active lives with no significant side effects of treatment.
Learning points
-
Conventional therapy resulted in a suboptimal response, with a lack of improvement of clinical signs and symptoms.
-
Side effects of conventional therapy included nausea, diarrhea, abdominal pain, nephrocalcinosis, and hyperparathyroidism, which affected the patients’ quality of life and adherence to treatment.
-
Burosumab demonstrated marked improvements in the biochemical markers of rickets, in addition to reducing pain, muscle weakness, and fatigue.
-
There were no significant side effects associated with burosumab therapy.
